Survodutide

10mg Vial

2 September 2026Updated 2 September 2026

Survodutide

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Survodutide.

Create free account Member login

Full range of benefits for Survodutide

Reduces appetite and caloric intake

Supports weight loss via GLP-1/glucagon co-agonism

May lower HbA1c and improve glycaemic control

Increases energy expenditure through glucagon activity

May reduce liver fat and markers of NAFLD/NASH

Can decrease visceral fat and overall body fat mass

May improve lipid parameters (triglycerides, HDL)

Potential to enhance insulin sensitivity

Designed for sustained activity with less frequent dosing

May lower inflammatory and cardiometabolic biomarkers

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 14 known interactions

Synergistic(3)Compatible(3)Monitor(4)Avoid(4)

Generally well-tolerated alongside this peptide

Statins

No expected pharmacokinetic interaction and can be coadministered routinely for cardiovascular risk management.

ACE inhibitors / ARBs

No direct interaction anticipated; commonly co-prescribed for blood pressure and cardiorenal protection without dose adjustment.

Proton pump inhibitors (PPIs)

Altered gastric pH from PPIs does not materially affect peptide exposure, making routine coadministration acceptable.

All interaction categories

Synergistic (3)

Metformin: Complementary glycaemic mechanisms provide additive blood-glucose lowering and weight-management benefits when used together.
SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin): Independent renal glucose excretion mechanisms produce complementary improvements in glycaemic control, weight and cardiorenal risk profile.
Pramlintide (amylin analogue): Adds post‑prandial glucose control and satiety effects that can enhance overall glycaemic and weight outcomes but may increase gastrointestinal adverse effects.

Compatible (3)

Statins: No expected pharmacokinetic interaction and can be coadministered routinely for cardiovascular risk management.
ACE inhibitors / ARBs: No direct interaction anticipated; commonly co-prescribed for blood pressure and cardiorenal protection without dose adjustment.
Proton pump inhibitors (PPIs): Altered gastric pH from PPIs does not materially affect peptide exposure, making routine coadministration acceptable.

Monitor (4)

Insulin and sulfonylureas: Increased risk of hypoglycaemia requires blood‑glucose monitoring and consideration of dose reduction of insulin or secretagogues.
Warfarin and other vitamin K antagonists: Changes in oral intake, weight and gastrointestinal absorption after initiation may alter INR, so frequent INR monitoring is recommended.
Oral hormonal contraceptives: Slowed gastric emptying and gastrointestinal adverse effects can alter oral contraceptive absorption or tolerability, so counsel patients and monitor for breakthrough bleeding.
Levothyroxine: Delayed gastric emptying may reduce levothyroxine absorption, so monitor thyroid function tests and consider dose‑timing adjustments.

Avoid (4)

Other incretin‑based therapies (DPP‑4 inhibitors, additional GLP‑1 RAs): Therapeutic redundancy can increase gastrointestinal adverse effects with limited incremental benefit, so reassess necessity before combining.
Medications with narrow therapeutic windows (e.g., digoxin, certain anticonvulsants): Altered gastric emptying and weight changes may affect absorption and exposure, requiring clinical review and possible drug‑level or effect monitoring.
DPP‑4 inhibitors: Limited additive glycaemic benefit and theoretical pancreatitis signal warrant careful evaluation before combination.
Pregnancy and lactation: Limited safety data in pregnancy and breastfeeding necessitate careful risk–benefit assessment and generally avoidance unless clearly indicated by a specialist.